Gut-Skin Axis: Current Knowledge of the Interrelationship between Microbial Dysbiosis and Skin Conditions

Britta De Pessemier, Lynda Grine, Melanie Debaere, Aglaya Maes, Bernhard Paetzold, Chris Callewaert, Britta De Pessemier, Lynda Grine, Melanie Debaere, Aglaya Maes, Bernhard Paetzold, Chris Callewaert

Abstract

The microbiome plays an important role in a wide variety of skin disorders. Not only is the skin microbiome altered, but also surprisingly many skin diseases are accompanied by an altered gut microbiome. The microbiome is a key regulator for the immune system, as it aims to maintain homeostasis by communicating with tissues and organs in a bidirectional manner. Hence, dysbiosis in the skin and/or gut microbiome is associated with an altered immune response, promoting the development of skin diseases, such as atopic dermatitis, psoriasis, acne vulgaris, dandruff, and even skin cancer. Here, we focus on the associations between the microbiome, diet, metabolites, and immune responses in skin pathologies. This review describes an exhaustive list of common skin conditions with associated dysbiosis in the skin microbiome as well as the current body of evidence on gut microbiome dysbiosis, dietary links, and their interplay with skin conditions. An enhanced understanding of the local skin and gut microbiome including the underlying mechanisms is necessary to shed light on the microbial involvement in human skin diseases and to develop new therapeutic approaches.

Keywords: acne vulgaris; atopic dermatitis; dandruff; dietary; gut dysbiosis; probiotics; psoriasis; rosacea; skin cancer; skin microbiome; wound healing.

Conflict of interest statement

The authors declare no conflict of interest. B.P is employee and stockholder of S-Biomedic. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Inflammatory and microbial influences between the gut and skin for a healthy state (left) and a dysbiotic state (right): The intestinal and epidermal barriers are connected through the systemic circulation (blood and lymph) and are visualized here together in a simplistic manner. The dysbiotic state is characterized by an impaired gut barrier (imbalance in gut microbiome, reduced mucus layer, reduced IgA secretion, barrier disruption, intestinal permeation into the bloodstream, and gut inflammation) and an impaired skin barrier (imbalance in skin microbiome, reduced human and microbial antimicrobial peptides (AMP) production, skin rashes/thickening/lesions, and skin inflammation). Gut and skin dysbiosis are connected through an immune imbalance (Th2 skewing in this example), whereas crosstalk can be bidirectional.

References

    1. Gallo R.L. Human skin is the largest epithelial surface for interaction with microbes. J. Investig. Dermatol. 2017;137:1213–1214. doi: 10.1016/j.jid.2016.11.045.
    1. Helander H.F., Fändriks L. Surface area of the digestive tract–revisited. Scand. J. Gastroenterol. 2014;49:681–689. doi: 10.3109/00365521.2014.898326.
    1. Thursby E., Juge N. Introduction to the human gut microbiota. Biochem. J. 2017;474:1823–1836. doi: 10.1042/BCJ20160510.
    1. Williams R. Benefit and mischief from commensal bacteria. J. Clin. Pathol. 1973;26:811. doi: 10.1136/jcp.26.11.811.
    1. Savage D.C. Microbial ecology of the gastrointestinal tract. Annu. Rev. Microbiol. 1977;31:107–133. doi: 10.1146/annurev.mi.31.100177.000543.
    1. Grice E.A., Segre J.A. The skin microbiome. Nat. Rev. Microbiol. 2011;9:244–253. doi: 10.1038/nrmicro2537.
    1. Arck P., Handjiski B., Hagen E., Pincus M., Bruenahl C., Bienenstock J., Paus R. Is there a ‘gut–brain–skin axis’? Exp. Dermatol. 2010;19:401–405. doi: 10.1111/j.1600-0625.2009.01060.x.
    1. Shah K.R., Boland C.R., Patel M., Thrash B., Menter A. Cutaneous manifestations of gastrointestinal disease: Part I. J. Am. Acad. Dermatol. 2013;68:189.e1–189.e21. doi: 10.1016/j.jaad.2012.10.037.
    1. Thrash B., Patel M., Shah K.R., Boland C.R., Menter A. Cutaneous manifestations of gastrointestinal disease: Part II. J. Am. Acad. Dermatol. 2013;68:211.e1–211.e33. doi: 10.1016/j.jaad.2012.10.036.
    1. Gloster H.M., Gebauer L.E., Mistur R.L. Absolute Dermatology Review. Springer; Berlin/Heidelberg, Germany: 2016. Cutaneous manifestations of gastrointestinal disease; pp. 171–179.
    1. O’Neill C.A., Monteleone G., McLaughlin J.T., Paus R. The gut-skin axis in health and disease: A paradigm with therapeutic implications. BioEssays. 2016;38:1167–1176. doi: 10.1002/bies.201600008.
    1. Shaykhiev R., Bals R. Interactions between epithelial cells and leukocytes in immunity and tissue homeostasis. J. Leukoc. Biol. 2007;82:1–15. doi: 10.1189/jlb.0207096.
    1. Bach J.F. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 2002;347:911–920. doi: 10.1056/NEJMra020100.
    1. Madison K.C. Barrier function of the skin:“la raison d’etre” of the epidermis. J. Investig. Dermatol. 2003;121:231–241. doi: 10.1046/j.1523-1747.2003.12359.x.
    1. Lange L., Huang Y., Busk P.K. Microbial decomposition of keratin in nature—a new hypothesis of industrial relevance. Appl. Microbiol. Biotechnol. 2016;100:2083–2096. doi: 10.1007/s00253-015-7262-1.
    1. Pelaseyed T., Bergström J.H., Gustafsson J.K., Ermund A., Birchenough G.M., Schütte A., van der Post S., Svensson F., Rodríguez-Piñeiro A.M., Nyström E.E., et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol. Rev. 2014;260:8–20. doi: 10.1111/imr.12182.
    1. Kim Y.S., Ho S.B. Intestinal goblet cells and mucins in health and disease: Recent insights and progress. Curr. Gastroenterol. Rep. 2010;12:319–330. doi: 10.1007/s11894-010-0131-2.
    1. Janeway C.A., Jr., Travers P., Walport M., Shlomchik M.J. Immunobiology: The Immune System in Health and Disease. 5th ed. Garland Science; New York, NY, USA: 2001. The front line of host defense.
    1. Schmid-Wendtner M.H., Korting H.C. The pH of the skin surface and its impact on the barrier function. Skin Pharmacol. Physiol. 2006;19:296–302. doi: 10.1159/000094670.
    1. Nakatsuji T., Kao M.C., Zhang L., Zouboulis C.C., Gallo R.L., Huang C.M. Sebum free fatty acids enhance the innate immune defense of human sebocytes by upregulating β-defensin-2 expression. J. Investig. Dermatol. 2010;130:985–994. doi: 10.1038/jid.2009.384.
    1. Dahlhoff M., Zouboulis C.C., Schneider M.R. Expression of dermcidin in sebocytes supports a role for sebum in the constitutive innate defense of human skin. J. Dermatol. Sci. 2016;81:124–126. doi: 10.1016/j.jdermsci.2015.11.013.
    1. Patricia J.J., Dhamoon A.S. Physiology, Digestion. [(accessed on 2 November 2020)];2019 Available online: .
    1. Brown E.M., Sadarangani M., Finlay B.B. The role of the immune system in governing host-microbe interactions in the intestine. Nat. Immunol. 2013;14:660–667. doi: 10.1038/ni.2611.
    1. Spits H., Cupedo T. Innate lymphoid cells: Emerging insights in development, lineage relationships, and function. Annu. Rev. Immunol. 2012;30:647–675. doi: 10.1146/annurev-immunol-020711-075053.
    1. Braff M.H., Zaiou M., Fierer J., Nizet V., Gallo R.L. Keratinocyte production of cathelicidin provides direct activity against bacterial skin pathogens. Infect. Immun. 2005;73:6771–6781. doi: 10.1128/IAI.73.10.6771-6781.2005.
    1. Gläser R., Harder J., Lange H., Bartels J., Christophers E., Schröder J.M. Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nat. Immunol. 2005;6:57–64. doi: 10.1038/ni1142.
    1. Yamasaki K., Schauber J., Coda A., Lin H., Dorschner R.A., Schechter N.M., Bonnart C., Descargues P., Hovnanian A., Gallo R.L. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J. 2006;20:2068–2080. doi: 10.1096/fj.06-6075com.
    1. Johansson M.E., Sjövall H., Hansson G.C. The gastrointestinal mucus system in health and disease. Nat. Rev. Gastroenterol. Hepatol. 2013;10:352. doi: 10.1038/nrgastro.2013.35.
    1. Cheng H., Leblond C. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine I. Columnar cell. Am. J. Anat. 1974;141:461–479. doi: 10.1002/aja.1001410403.
    1. Podolsky D.K., Lynch-Devaney K., Stow J.L., Oates P., Murgue B., DeBeaumont M., Sands B.E., Mahida Y.R. Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. J. Biol. Chem. 1993;268:6694–6702. doi: 10.1016/S0021-9258(18)53305-6.
    1. Johansson M.E., Larsson J.M.H., Hansson G.C. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host–microbial interactions. Proc. Natl. Acad. Sci. USA. 2011;108:4659–4665. doi: 10.1073/pnas.1006451107.
    1. Vaishnava S., Behrendt C.L., Ismail A.S., Eckmann L., Hooper L.V. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc. Natl. Acad. Sci. USA. 2008;105:20858–20863. doi: 10.1073/pnas.0808723105.
    1. Qiu J., Heller J.J., Guo X., Zong-ming E.C., Fish K., Fu Y.X., Zhou L. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity. 2012;36:92–104. doi: 10.1016/j.immuni.2011.11.011.
    1. Sonnenberg G.F., Monticelli L.A., Elloso M.M., Fouser L.A., Artis D. CD4+ lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity. 2011;34:122–134. doi: 10.1016/j.immuni.2010.12.009.
    1. Niess J.H., Brand S., Gu X., Landsman L., Jung S., McCormick B.A., Vyas J.M., Boes M., Ploegh H.L., Fox J.G., et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science. 2005;307:254–258. doi: 10.1126/science.1102901.
    1. Macpherson A.J., Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science. 2004;303:1662–1665. doi: 10.1126/science.1091334.
    1. Neutra M.R., Pringault E., Kraehenbuhl J.P. Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu. Rev. Immunol. 1996;14:275–300. doi: 10.1146/annurev.immunol.14.1.275.
    1. Barker N. Adult intestinal stem cells: Critical drivers of epithelial homeostasis and regeneration. Nat. Rev. Mol. Cell Biol. 2014;15:19–33. doi: 10.1038/nrm3721.
    1. Hsieh E.A., Chai C.M., Benito O., Neese R.A., Hellerstein M.K. Dynamics of keratinocytes in vivo using 2H2O labeling: A sensitive marker of epidermal proliferation state. J. Investig. Dermatol. 2004;123:530–536. doi: 10.1111/j.0022-202X.2004.23303.x.
    1. Sekirov I., Russell S.L., Antunes L.C.M., Finlay B.B. Gut microbiota in health and disease. Physiol. Rev. 2010;90:859–904. doi: 10.1152/physrev.00045.2009.
    1. Capone K.A., Dowd S.E., Stamatas G.N., Nikolovski J. Diversity of the human skin microbiome early in life. J. Investig. Dermatol. 2011;131:2026–2032. doi: 10.1038/jid.2011.168.
    1. Dzutsev A., Goldszmid R.S., Viaud S., Zitvogel L., Trinchieri G. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur. J. Immunol. 2015;45:17–31. doi: 10.1002/eji.201444972.
    1. Vlachos C., Gaitanis G., Katsanos K.H., Christodoulou D.K., Tsianos E., Bassukas I.D. Psoriasis and inflammatory bowel disease: Links and risks. Psoriasis. 2016;6:73.
    1. Clarke G., Stilling R.M., Kennedy P.J., Stanton C., Cryan J.F., Dinan T.G. Minireview: Gut microbiota: The neglected endocrine organ. Mol. Endocrinol. 2014;28:1221–1238. doi: 10.1210/me.2014-1108.
    1. Chapat L., Chemin K., Dubois B., Bourdet-Sicard R., Kaiserlian D. Lactobacillus casei reduces CD8+ T cell-mediated skin inflammation. Eur. J. Immunol. 2004;34:2520–2528. doi: 10.1002/eji.200425139.
    1. Guéniche A., Benyacoub J., Buetler T.M., Smola H., Blum S. Supplementation with oral probiotic bacteria maintains cutaneous immune homeostasis after UV exposure. Eur. J. Dermatol. 2006;16:511–517.
    1. Benyacoub J., Bosco N., Blanchard C., Demont A., Philippe D., Castiel-Higounenc I., Guéniche A. Immune modulation property of Lactobacillus paracasei NCC2461 (ST11) strain and impact on skin defences. Benef. Microbes. 2014;5:129–136. doi: 10.3920/BM2013.0014.
    1. Belkaid Y., Tamoutounour S. The influence of skin microorganisms on cutaneous immunity. Nat. Rev. Immunol. 2016;16:353–366. doi: 10.1038/nri.2016.48.
    1. Johnson L.R., Christensen J., Jackson M.J. Physiology of the Gastrointestinal Tract. 2nd ed. Raven; New York, NY, USA: 1987. pp. 665–693.
    1. Ipci K., Altıntoprak N., Muluk N.B., Senturk M., Cingi C. The possible mechanisms of the human microbiome in allergic diseases. Eur. Arch. Oto-Rhino. 2017;274:617–626. doi: 10.1007/s00405-016-4058-6.
    1. LeBlanc J.G., Milani C., De Giori G.S., Sesma F., Van Sinderen D., Ventura M. Bacteria as vitamin suppliers to their host: A gut microbiota perspective. Curr. Opin. Biotechnol. 2013;24:160–168. doi: 10.1016/j.copbio.2012.08.005.
    1. Scott K.P., Gratz S.W., Sheridan P.O., Flint H.J., Duncan S.H. The influence of diet on the gut microbiota. Pharmacol. Res. 2013;69:52–60. doi: 10.1016/j.phrs.2012.10.020.
    1. Yazdanbakhsh M., Kremsner P.G., Van Ree R. Allergy, parasites, and hygiene hypothesis. Science. 2002;296:490–494. doi: 10.1126/science.296.5567.490.
    1. Mccall L.I., Callewaert C., Zhu Q., Song S.J., Bouslimani A., Minich J.J., Ernst M., Ruiz-Calderon J.F., Cavallin H., Pereira H.S., et al. Home chemical and microbial transitions across urbanization. Nat. Microbiol. 2020;5:108–115. doi: 10.1038/s41564-019-0593-4.
    1. Callewaert C., Helffer K.R., Lebaron P. Skin Microbiome and its Interplay with the Environment. Am. J. Clin. Dermatol. 2020;21:4–11. doi: 10.1007/s40257-020-00551-x.
    1. Guo X., Li J., Tang R., Zhang G., Zeng H., Wood R.J., Liu Z. High fat diet alters gut microbiota and the expression of paneth cell-antimicrobial peptides preceding changes of circulating inflammatory cytokines. Mediat. Inflamm. 2017;2017:9474896. doi: 10.1155/2017/9474896.
    1. Gee J., Wortley G., Johnson I., Price K., Rutten A., Houben G., Penninks A. Effects of saponins and glycoalkaloids on the permeability and viability of mammalian intestinal cells and on the integrity of tissue preparations in vitro. Toxicol. Vitr. 1996;10:117–128. doi: 10.1016/0887-2333(95)00113-1.
    1. Humbert P., Pelletier F., Dreno B., Puzenat E., Aubin F. Gluten intolerance and skin diseases. Eur. J. Dermatol. 2006;16:4–11.
    1. Fry L., Riches D., Seah P., Hoffbrand A. Clearance of skin lesions in dermatitis herpetiformis after gluten withdrawal. Lancet. 1973;301:288–291. doi: 10.1016/S0140-6736(73)91539-0.
    1. Grossi E., Cazzaniga S., Crotti S., Naldi L., Di Landro A., Ingordo V., Cusano F., Atzori L., Tripodi Cutrì F., Musumeci M., et al. The constellation of dietary factors in adolescent acne: A semantic connectivity map approach. J. Eur. Acad. Dermatol. Venereol. 2016;30:96–100. doi: 10.1111/jdv.12878.
    1. Bosman E.S., Albert A.Y., Lui H., DUTZ J.P., Vallance B.A. Skin exposure to Narrow Band Ultraviolet (UV) B light modulates the human intestinal microbiome. Front. Microbiol. 2019;10:2410. doi: 10.3389/fmicb.2019.02410.
    1. Brough H.A., Liu A.H., Sicherer S., Makinson K., Douiri A., Brown S.J., Stephens A.C., McLean W.I., Turcanu V., Wood R.A., et al. Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy. J. Allergy Clin. Immunol. 2015;135:164–170. doi: 10.1016/j.jaci.2014.10.007.
    1. Bartnikas L.M., Gurish M.F., Burton O.T., Leisten S., Janssen E., Oettgen H.C., Beaupré J., Lewis C.N., Austen K.F., Schulte S., et al. Epicutaneous sensitization results in IgE-dependent intestinal mast cell expansion and food-induced anaphylaxis. J. Allergy Clin. Immunol. 2013;131:451–460. doi: 10.1016/j.jaci.2012.11.032.
    1. Hoh R.A., Joshi S.A., Lee J.Y., Martin B.A., Varma S., Kwok S., Nielsen S.C., Nejad P., Haraguchi E., Dixit P.S., et al. Origins and clonal convergence of gastrointestinal IgE+ B cells in human peanut allergy. Sci. Immunol. 2020;5:eaay4209. doi: 10.1126/sciimmunol.aay4209.
    1. Huang B.L., Chandra S., Shih D.Q. Skin manifestations of inflammatory bowel disease. Front. Physiol. 2012;3:13. doi: 10.3389/fphys.2012.00013.
    1. Bowe W.P., Logan A.C. Acne vulgaris, probiotics and the gut-brain-skin axis-back to the future? Gut Pathog. 2011;3:1–11. doi: 10.1186/1757-4749-3-1.
    1. Lyte M. Microbial Endocrinology: The Microbiota-Gut-Brain Axis in Health and Disease. Springer; Berlin/Heidelberg, Germany: 2014. Microbial endocrinology and the microbiota-gut-brain axis; pp. 3–24.
    1. Rea K., Dinan T.G., Cryan J.F. The microbiome: A key regulator of stress and neuroinflammation. Neurobiol. Stress. 2016;4:23–33. doi: 10.1016/j.ynstr.2016.03.001.
    1. Cummings J.H., Macfarlane G.T. Role of intestinal bacteria in nutrient metabolism. Clin. Nutr. 1997;16:3–11. doi: 10.1016/S0261-5614(97)80252-X.
    1. Mariadason J., Catto-Smith A., Gibson P. Modulation of distal colonic epithelial barrier function by dietary fibre in normal rats. Gut. 1999;44:394–399. doi: 10.1136/gut.44.3.394.
    1. Lomholt H.B., Kilian M. Population genetic analysis of Propionibacterium acnes identifies a subpopulation and epidemic clones associated with acne. PLoS ONE. 2010;5:e12277. doi: 10.1371/journal.pone.0012277.
    1. Lomholt H., Scholz C., Brüggemann H., Tettelin H., Kilian M. A comparative study of Cutibacterium (Propionibacterium) acnes clones from acne patients and healthy controls. Anaerobe. 2017;47:57–63. doi: 10.1016/j.anaerobe.2017.04.006.
    1. McDowell A., Gao A., Barnard E., Fink C., Murray P.I., Dowson C.G., Nagy I., Lambert P.A., Patrick S. A novel multilocus sequence typing scheme for the opportunistic pathogen Propionibacterium acnes and characterization of type I cell surface-associated antigens. Microbiology. 2011;157:1990–2003. doi: 10.1099/mic.0.049676-0.
    1. Paugam C., Corvec S., Saint-Jean M., Le Moigne M., Khammari A., Boisrobert A., Nguyen J., Gaultier A., Dréno B. Propionibacterium acnes phylotypes and acne severity: An observational prospective study. J. Eur. Acad. Dermatol. Venereol. 2017;31:e398–e399. doi: 10.1111/jdv.14206.
    1. Fitz-Gibbon S., Tomida S., Chiu B.H., Nguyen L., Du C., Liu M., Elashoff D., Erfe M.C., Loncaric A., Kim J., et al. Propionibacterium acnes strain populations in the human skin microbiome associated with acne. J. Investig. Dermatol. 2013;133:2152–2160. doi: 10.1038/jid.2013.21.
    1. Karoglan A., Paetzold B., De Lima J.P., Brüggemann H., Tüting T., Schanze D., Güell M., Gollnick H. Safety and efficacy of topically applied selected cutibacterium acnes strains over five weeks in patients with acne vulgaris: An open-label, pilot study. Acta Derm. Venereol. 2019;99:1253–1257. doi: 10.2340/00015555-3323.
    1. Johnson T., Kang D., Barnard E., Li H. Strain-level differences in porphyrin production and regulation in Propionibacterium acnes elucidate disease associations. Msphere. 2016;1 doi: 10.1128/mSphere.00023-15.
    1. Barnard E., Shi B., Kang D., Craft N., Li H. The balance of metagenomic elements shapes the skin microbiome in acne and health. Sci. Rep. 2016;6:1–12. doi: 10.1038/srep39491.
    1. Lheure C., Grange P.A., Ollagnier G., Morand P., Désiré N., Sayon S., Corvec S., Raingeaud J., Marcelin A.G., Calvez V., et al. TLR-2 recognizes Propionibacterium acnes CAMP factor 1 from highly inflammatory strains. PLoS ONE. 2016;11:e0167237. doi: 10.1371/journal.pone.0167237.
    1. Kong H.H., Oh J., Deming C., Conlan S., Grice E.A., Beatson M.A., Nomicos E., Polley E.C., Komarow H.D., Murray P.R., et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22:850–859. doi: 10.1101/gr.131029.111.
    1. Shi B., Bangayan N.J., Curd E., Taylor P.A., Gallo R.L., Leung D.Y., Li H. The skin microbiome is different in pediatric versus adult atopic dermatitis. J. Allergy Clin. Immunol. 2016;138:1233–1236. doi: 10.1016/j.jaci.2016.04.053.
    1. Oh J., Freeman A.F., Park M., Sokolic R., Candotti F., Holland S.M., Segre J.A., Kong H.H., NISC Comparative Sequencing Program The altered landscape of the human skin microbiome in patients with primary immunodeficiencies. Genome Res. 2013;23:2103–2114. doi: 10.1101/gr.159467.113.
    1. Chng K.R., Tay A.S.L., Li C., Ng A.H.Q., Wang J., Suri B.K., Matta S.A., McGovern N., Janela B., Wong X.F.C.C., et al. Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare. Nat. Microbiol. 2016;1:1–10. doi: 10.1038/nmicrobiol.2016.106.
    1. Alekseyenko A.V., Perez-Perez G.I., De Souza A., Strober B., Gao Z., Bihan M., Li K., Methé B.A., Blaser M.J. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome. 2013;1:31. doi: 10.1186/2049-2618-1-31.
    1. Statnikov A., Alekseyenko A.V., Li Z., Henaff M., Perez-Perez G.I., Blaser M.J., Aliferis C.F. Microbiomic signatures of psoriasis: Feasibility and methodology comparison. Sci. Rep. 2013;3:2620. doi: 10.1038/srep02620.
    1. Takemoto A., Cho O., Morohoshi Y., Sugita T., Muto M. Molecular characterization of the skin fungal microbiome in patients with psoriasis. J. Dermatol. 2015;42:166–170. doi: 10.1111/1346-8138.12739.
    1. Chang H.W., Yan D., Singh R., Liu J., Lu X., Ucmak D., Lee K., Afifi L., Fadrosh D., Leech J., et al. Alteration of the cutaneous microbiome in psoriasis and potential role in Th17 polarization. Microbiome. 2018;6:154. doi: 10.1186/s40168-018-0533-1.
    1. Yerushalmi M., Elalouf O., Anderson M., Chandran V. The skin microbiome in psoriatic disease: A systematic review and critical appraisal. J. Transl. Autoimmun. 2019;2:100009. doi: 10.1016/j.jtauto.2019.100009.
    1. Guet-Revillet H., Jais J.P., Ungeheuer M.N., Coignard-Biehler H., Duchatelet S., Delage M., Lam T., Hovnanian A., Lortholary O., Nassif X., et al. The microbiological landscape of anaerobic infections in hidradenitis suppurativa: A prospective metagenomic study. Clin. Infect. Dis. 2017;65:282–291. doi: 10.1093/cid/cix285.
    1. Assan F., Gottlieb J., Tubach F., Lebbah S., Guigue N., Hickman G., Pape E., Madrange M., Delaporte E., Sendid B., et al. Anti-Saccharomyces cerevisiae IgG and IgA antibodies are associated with systemic inflammation and advanced disease in hidradenitis suppurativa. J. Allergy Clin. Immunol. 2020;146:452–455. doi: 10.1016/j.jaci.2020.01.045.
    1. Forton F., Seys B. Density of Demodex folliculorum in rosacea: A case-control study using standardized skin-surface biopsy. Br. J. Dermatol. 1993;128:650–659. doi: 10.1111/j.1365-2133.1993.tb00261.x.
    1. Woo Y.R., Lim J.H., Cho D.H., Park H.J. Rosacea: Molecular mechanisms and management of a chronic cutaneous inflammatory condition. Int. J. Mol. Sci. 2016;17:1562. doi: 10.3390/ijms17091562.
    1. Dawson T.L., Jr. Malassezia globosa and restricta: Breakthrough understanding of the etiology and treatment of dandruff and seborrheic dermatitis through whole-genome analysis. J. Investig. Dermatol. Symp. Proc. 2007;12:15–19. doi: 10.1038/sj.jidsymp.5650049.
    1. MacKee G.M., Lewis G.M., WTTA of Martha. Spence J., WTTA of Mary. Hopper E. Dandruff and seborrhea: I. flora of “normal” and diseased scalps. J. Investig. Dermatol. 1938;1:131–139. doi: 10.1038/jid.1938.14.
    1. Xu Z., Wang Z., Yuan C., Liu X., Yang F., Wang T., Wang J., Manabe K., Qin O., Wang X., et al. Dandruff is associated with the conjoined interactions between host and microorganisms. Sci. Rep. 2016;6:1–9. doi: 10.1038/srep24877.
    1. Clavaud C., Jourdain R., Bar-Hen A., Tichit M., Bouchier C., Pouradier F., El Rawadi C., Guillot J., Ménard-Szczebara F., Breton L., et al. Dandruff is associated with disequilibrium in the proportion of the major bacterial and fungal populations colonizing the scalp. PLoS ONE. 2013;8:e58203. doi: 10.1371/annotation/bcff4a59-10b7-442a-8181-12fa69209e57.
    1. Skinner R.B., Jr., Light W.H., Leonardi C., Bale G.F., Rosenberg E.W. A molecular approach to alopecia areata. J. Investig. Dermatol. 1995;104:3S. doi: 10.1038/jid.1995.27.
    1. Rudnicka L., Lukomska M. Alternaria scalp infection in a patient with alopecia areata. Coexistence or causative relationship? J. Dermatol. Case Rep. 2012;6:120. doi: 10.3315/jdcr.2012.1120.
    1. Pinto D., Sorbellini E., Marzani B., Rucco M., Giuliani G., Rinaldi F. Scalp bacterial shift in Alopecia areata. PLoS ONE. 2019;14:e0215206. doi: 10.1371/journal.pone.0215206.
    1. Wood D.L., Lachner N., Tan J.M., Tang S., Angel N., Laino A., Linedale R., Lê Cao K.A., Morrison M., Frazer I.H., et al. A natural history of actinic keratosis and cutaneous squamous cell carcinoma microbiomes. MBio. 2018;9 doi: 10.1128/mBio.01432-18.
    1. Cheng J., Zens M.S., Duell E., Perry A.E., Chapman M.S., Karagas M.R. History of allergy and atopic dermatitis in relation to squamous cell and basal cell carcinoma of the skin. Cancer Epidemiol. Prev. Biomarkers. 2015;24:749–754. doi: 10.1158/1055-9965.EPI-14-1243.
    1. Mrázek J., Mekadim C., Kučerová P., Švejstil R., Salmonová H., Vlasáková J., Tarasová R., Čížková J., Červinková M. Melanoma-related changes in skin microbiome. Folia Microbiol. 2019;64:435–442. doi: 10.1007/s12223-018-00670-3.
    1. Sherwani M.A., Tufail S., Muzaffar A.F., Yusuf N. The skin microbiome and immune system: Potential target for chemoprevention? Photodermatol. Photoimmunol. Photomed. 2018;34:25–34. doi: 10.1111/phpp.12334.
    1. Sikorska H., Smoragiewicz W. Role of probiotics in the prevention and treatment of meticillin-resistant Staphylococcus aureus infections. Int. J. Antimicrob. Agents. 2013;42:475–481. doi: 10.1016/j.ijantimicag.2013.08.003.
    1. Guo H., Zheng Y., Wang B., Li Z. A note on an improved self-healing group key distribution scheme. Sensors. 2015;15:25033–25038. doi: 10.3390/s151025033.
    1. Smith R.N., Mann N.J., Braue A., Mäkeläinen H., Varigos G.A. A low-glycemic-load diet improves symptoms in acne vulgaris patients: A randomized controlled trial. Am. J. Clin. Nutr. 2007;86:107–115. doi: 10.1093/ajcn/86.1.107.
    1. Song H., Yoo Y., Hwang J., Na Y.C., Kim H.S. Faecalibacterium prausnitzii subspecies–level dysbiosis in the human gut microbiome underlying atopic dermatitis. J. Allergy Clin. Immunol. 2016;137:852–860. doi: 10.1016/j.jaci.2015.08.021.
    1. Kalliomäki M., Kirjavainen P., Eerola E., Kero P., Salminen S., Isolauri E. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J. Allergy Clin. Immunol. 2001;107:129–134. doi: 10.1067/mai.2001.111237.
    1. Penders J., Thijs C., van den Brandt P.A., Kummeling I., Snijders B., Stelma F., Adams H., van Ree R., Stobberingh E.E. Gut microbiota composition and development of atopic manifestations in infancy: The KOALA Birth Cohort Study. Gut. 2007;56:661–667. doi: 10.1136/gut.2006.100164.
    1. Lee E., Lee S.Y., Kang M.J., Kim K., Won S., Kim B.J., Choi K.Y., Kim B.S., Cho H.J., Kim Y., et al. Clostridia in the gut and onset of atopic dermatitis via eosinophilic inflammation. Ann. Allergy Asthma Immunol. 2016;117:91–92. doi: 10.1016/j.anai.2016.04.019.
    1. Kirjavainen P., Arvola T., Salminen S., Isolauri E. Aberrant composition of gut microbiota of allergic infants: A target of bifidobacterial therapy at weaning? Gut. 2002;51:51–55. doi: 10.1136/gut.51.1.51.
    1. Watanabe S., Narisawa Y., Arase S., Okamatsu H., Ikenaga T., Tajiri Y., Kumemura M. Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects. J. Allergy Clin. Immunol. 2003;111:587–591. doi: 10.1067/mai.2003.105.
    1. Fujimura K.E., Sitarik A.R., Havstad S., Lin D.L., Levan S., Fadrosh D., Panzer A.R., LaMere B., Rackaityte E., Lukacs N.W., et al. Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation. Nat. Med. 2016;22:1187–1191. doi: 10.1038/nm.4176.
    1. Fiocchi A., Pawankar R., Cuello-Garcia C., Ahn K., Al-Hammadi S., Agarwal A., Beyer K., Burks W., Canonica G.W., Ebisawa M., et al. World allergy organization-McMaster university guidelines for allergic disease prevention (GLAD-P): Probiotics. World Allergy Organ. J. 2015;8:1–13. doi: 10.1186/s40413-015-0055-2.
    1. Sikora M., Stec A., Chrabaszcz M., Knot A., Waskiel-Burnat A., Rakowska A., Olszewska M., Rudnicka L. Gut microbiome in psoriasis: An updated review. Pathogens. 2020;9:463. doi: 10.3390/pathogens9060463.
    1. Grine L., Steeland S., Van Ryckeghem S., Ballegeer M., Lienenklaus S., Weiss S., Sanders N.N., Vandenbroucke R.E., Libert C. Topical imiquimod yields systemic effects due to unintended oral uptake. Sci. Rep. 2016;6:20134. doi: 10.1038/srep20134.
    1. Jung G.W., Tse J.E., Guiha I., Rao J. Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of an acne treatment regimen with and without a probiotic supplement and minocycline in subjects with mild to moderate acne. J. Cutan. Med. Surg. 2013;17:114–122. doi: 10.2310/7750.2012.12026.
    1. Wu J.J., Nguyen T.U., Poon K.Y.T., Herrinton L.J. The association of psoriasis with autoimmune diseases. J. Am. Acad. Dermatol. 2012;67:924–930. doi: 10.1016/j.jaad.2012.04.039.
    1. Pietrzak D., Pietrzak A., Krasowska D., Borzęcki A., Franciszkiewicz-Pietrzak K., Polkowska-Pruszyńska B., Baranowska M., Reich K. Digestive system in psoriasis: An update. Arch. Dermatol. Res. 2017;309:679–693. doi: 10.1007/s00403-017-1775-7.
    1. Yeh N.L., Hsu C.Y., Tsai T.F., Chiu H.Y. Gut microbiome in psoriasis is perturbed differently during secukinumab and ustekinumab therapy and associated with response to treatment. Clin. Drug Investig. 2019;39:1195–1203. doi: 10.1007/s40261-019-00849-7.
    1. Wark K.J., Cains G.D. Dermatology and Therapy. Vol. 11. Springer; Cham, Switzerland: 2020. The Microbiome in Hidradenitis Suppurativa: A Review; pp. 39–52.
    1. Brooks M. Gut microbe curbs systemic inflammation in psoriasis; Proceedings of the 29th European Academy of Dermatology and Venereology Congress (EADV); Vienna, Austria. 29–31 October 2020.
    1. Rebora A., Drago F., Parodi A. May Helicohacter pylori be important for dermatologists. Dermatology. 1995;191:6–8. doi: 10.1159/000246470.
    1. Parodi A., Paolino S., Greco A., Drago F., Mansi C., Rebora A., Parodi A., Savarino V. Small intestinal bacterial overgrowth in rosacea: Clinical effectiveness of its eradication. Clin. Gastroenterol. Hepatol. 2008;6:759–764. doi: 10.1016/j.cgh.2008.02.054.
    1. Nam J.H., Yun Y., Kim H.S., Kim H.N., Jung H.J., Chang Y., Ryu S., Shin H., Kim H.L., Kim W.S. Rosacea and its association with enteral microbiota in Korean females. Exp. Dermatol. 2018;27:37–42. doi: 10.1111/exd.13398.
    1. Reygagne P., Bastien P., Couavoux M., Philippe D., Renouf M., Castiel-Higounenc I., Gueniche A. The positive benefit of Lactobacillus paracasei NCC2461 ST11 in healthy volunteers with moderate to severe dandruff. Benef. Microbes. 2017;8:671–680. doi: 10.3920/BM2016.0144.
    1. Moreno-Arrones O., Serrano-Villar S., Perez-Brocal V., Saceda-Corralo D., Morales-Raya C., Rodrigues-Barata R., Moya A., Jaen-Olasolo P., Vano-Galvan S. Analysis of the gut microbiota in alopecia areata: Identification of bacterial biomarkers. J. Eur. Acad. Dermatol. Venereol. 2020;34:400–405. doi: 10.1111/jdv.15885.
    1. Rebello D., Wang E., Yen E., Lio P.A., Kelly C.R. Hair growth in two alopecia patients after fecal microbiota transplant. ACG Case Rep. J. 2017;4:e107. doi: 10.14309/crj.2017.107.
    1. Chen J., Domingue J.C., Sears C.L. Seminars in Immunology. Volume 32. Elsevier; Amsterdam, The Netherlands: 2017. Microbiota dysbiosis in select human cancers: Evidence of association and causality; pp. 25–34.
    1. Guo Y., Liu W., Wu J. Helicobacter pylori infection and pancreatic cancer risk: A meta-analysis. J. Cancer Res. Ther. 2016;12:229.
    1. Pichon M., Burucoa C. Impact of the gastro-intestinal bacterial microbiome on Helicobacter-associated diseases. Healthcare. 2019;7:34. doi: 10.3390/healthcare7010034.
    1. Silva Y.P., Bernardi A., Frozza R.L. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front. Endocrinol. 2020;11:25. doi: 10.3389/fendo.2020.00025.
    1. Torki M., Gholamrezaei A., Mirbagher L., Danesh M., Kheiri S., Emami M.H. Vitamin D deficiency associated with disease activity in patients with inflammatory bowel diseases. Dig. Dis. Sci. 2015;60:3085–3091. doi: 10.1007/s10620-015-3727-4.
    1. Kammeyer A., Peters C.P., Meijer S.L., te Velde A.A. Anti-inflammatory effects of urocanic acid derivatives in models ex vivo and in vivo of inflammatory bowel disease. ISRN Inflamm. 2012;2012:898153. doi: 10.5402/2012/898153.
    1. Strandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Res. 2018;1693:128–133. doi: 10.1016/j.brainres.2018.03.015.
    1. Akiyama T., Carstens M.I., Carstens E. Transmitters and pathways mediating inhibition of spinal itch-signaling neurons by scratching and other counterstimuli. PLoS ONE. 2011;6:e22665. doi: 10.1371/journal.pone.0022665.
    1. Langan E., Lisztes E., Bíró T., Funk W., Kloepper J., Griffiths C., Paus R. Dopamine is a novel, direct inducer of catagen in human scalp hair follicles in vitro. Br. J. Dermatol. 2013;168:520–525. doi: 10.1111/bjd.12113.
    1. Lee H., Park M., Kim S., Park Choo H., Lee A., Lee C. Serotonin induces melanogenesis via serotonin receptor 2A. Br. J. Dermatol. 2011;165:1344–1348. doi: 10.1111/j.1365-2133.2011.10490.x.
    1. Yokoyama S., Hiramoto K., Koyama M., Ooi K. Impairment of skin barrier function via cholinergic signal transduction in a dextran sulphate sodium-induced colitis mouse model. Exp. Dermatol. 2015;24:779–784. doi: 10.1111/exd.12775.
    1. Miyazaki K., Masuoka N., Kano M., Iizuka R. Bifidobacterium fermented milk and galacto-oligosaccharides lead to improved skin health by decreasing phenols production by gut microbiota. Benef. Microbes. 2014;5:121–128. doi: 10.3920/BM2012.0066.
    1. Rhodes L.E., Darby G., Massey K.A., Clarke K.A., Dew T.P., Farrar M.D., Bennett S., Watson R.E., Williamson G., Nicolaou A. Oral green tea catechin metabolites are incorporated into human skin and protect against UV radiation-induced cutaneous inflammation in association with reduced production of pro-inflammatory eicosanoid 12-hydroxyeicosatetraenoic acid. Br. J. Nutr. 2013;110:891–900. doi: 10.1017/S0007114512006071.
    1. Giampieri F., Alvarez-Suarez J.M., Mazzoni L., Forbes-Hernandez T.Y., Gasparrini M., Gonzàlez-Paramàs A.M., Santos-Buelga C., Quiles J.L., Bompadre S., Mezzetti B., et al. Polyphenol-rich strawberry extract protects human dermal fibroblasts against hydrogen peroxide oxidative damage and improves mitochondrial functionality. Molecules. 2014;19:7798–7816. doi: 10.3390/molecules19067798.
    1. Gibson G.R., Hutkins R., Sanders M.E., Prescott S.L., Reimer R.A., Salminen S.J., Scott K., Stanton C., Swanson K.S., Cani P.D., et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 2017;14:491. doi: 10.1038/nrgastro.2017.75.
    1. Rizwan M., Rodriguez-Blanco I., Harbottle A., Birch-Machin M., Watson R., Rhodes L. Tomato paste rich in lycopene protects against cutaneous photodamage in humans in vivo: A randomized controlled trial. Br. J. Dermatol. 2011;164:154–162. doi: 10.1111/j.1365-2133.2010.10057.x.
    1. Yoon H.J., Jang M.S., Kim H.W., Song D.U., Nam K.I., Bae C.S., Kim S.J., Lee S.R., Ku C.S., Jang D.I., et al. Protective effect of diet supplemented with rice prolamin extract against DNCB-induced atopic dermatitis in BALB/c mice. BMC Complement. Altern. Med. 2015;15:1–7. doi: 10.1186/s12906-015-0892-0.
    1. Tundis R., Loizzo M., Bonesi M., Menichini F. Potential role of natural compounds against skin aging. Curr. Med. Chem. 2015;22:1515–1538. doi: 10.2174/0929867322666150227151809.
    1. Cordain L., Lindeberg S., Hurtado M., Hill K., Eaton S.B., Brand-Miller J. Acne vulgaris: A disease of Western civilization. Arch. Dermatol. 2002;138:1584–1590. doi: 10.1001/archderm.138.12.1584.
    1. Zouboulis C.C., Jourdan E., Picardo M. Acne is an inflammatory disease and alterations of sebum composition initiate acne lesions. J. Eur. Acad. Dermatol. Venereol. JEADV. 2014;28:527–532. doi: 10.1111/jdv.12298.
    1. Agak G.W., Qin M., Nobe J., Kim M.H., Krutzik S.R., Tristan G.R., Elashoff D., Garbán H.J., Kim J. Propionibacterium acnes induces an IL-17 response in acne vulgaris that is regulated by vitamin A and vitamin D. J. Investig. Dermatol. 2014;134:366–373. doi: 10.1038/jid.2013.334.
    1. Thiboutot D.M., Layton A.M., Eady E.A. IL-17: A key player in the P. acnes inflammatory cascade? J. Investig. Dermatol. 2014;134:307–310. doi: 10.1038/jid.2013.400.
    1. Mattii M., Lovászi M., Garzorz N., Atenhan A., Quaranta M., Lauffer F., Konstantinow A., Küpper M., Zouboulis C., Kemeny L., et al. Sebocytes contribute to skin inflammation by promoting the differentiation of T helper 17 cells. Br. J. Dermatol. 2018;178:722–730. doi: 10.1111/bjd.15879.
    1. Ben-Amitai D., Laron Z. Effect of insulin-like growth factor-1 deficiency or administration on the occurrence of acne. J. Eur. Acad. Dermatol. Venereol. 2011;25:950–954. doi: 10.1111/j.1468-3083.2010.03896.x.
    1. Melnik B.C., Schmitz G. Role of insulin, insulin-like growth factor-1, hyperglycaemic food and milk consumption in the pathogenesis of acne vulgaris. Exp. Dermatol. 2009;18:833–841. doi: 10.1111/j.1600-0625.2009.00924.x.
    1. Çerman A.A., Aktaş E., Altunay İ.K., Arıcı J.E., Tulunay A., Ozturk F.Y. Dietary glycemic factors, insulin resistance, and adiponectin levels in acne vulgaris. J. Am. Acad. Dermatol. 2016;75:155–162. doi: 10.1016/j.jaad.2016.02.1220.
    1. Nast A., Dréno B., Bettoli V., Bukvic Mokos Z., Degitz K., Dressler C., Finlay A.Y., Haedersdal M., Lambert J., Layton A., et al. European evidence-based (S3) guideline for the treatment of acne–update 2016–short version. J. Eur. Acad. Dermatol. Venereol. 2016;30:1261–1268. doi: 10.1111/jdv.13776.
    1. Iinuma K., Sato T., Akimoto N., Noguchi N., Sasatsu M., Nishijima S., Kurokawa I., Ito A. Involvement of Propionibacterium acnes in the augmentation of lipogenesis in hamster sebaceous glands in vivo and in vitro. J. Investig. Dermatol. 2009;129:2113–2119. doi: 10.1038/jid.2009.46.
    1. Yu Y., Champer J., Agak G.W., Kao S., Modlin R.L., Kim J. Different Propionibacterium acnes phylotypes induce distinct immune responses and express unique surface and secreted proteomes. J. Investig. Dermatol. 2016;136:2221–2228. doi: 10.1016/j.jid.2016.06.615.
    1. Dagnelie M.A., Corvec S., Saint-Jean M., Bourdès V., Nguyen J.M., Khammari A., Dréno B. Decrease in diversity of Propionibacterium acnes phylotypes in patients with severe acne on the back. Acta Derm. Venereol. 2018;98:262–267. doi: 10.2340/00015555-2847.
    1. Borelli C., Merk K., Schaller M., Jacob K., Vogeser M., Weindl G., Berger U., Plewig G. In vivo porphyrin production by P. acnes in untreated acne patients and its modulation by acne treatment. Acta Derm. Venereol. 2006;86:316–319. doi: 10.2340/00015555-0088.
    1. Kasimatis G., Fitz-Gibbon S., Tomida S., Wong M., Li H. Analysis of complete genomes of Propionibacterium acnes reveals a novel plasmid and increased pseudogenes in an acne associated strain. BioMed. Res. Int. 2013;2013 doi: 10.1155/2013/918320.
    1. Brüggemann H., Lomholt H.B., Tettelin H., Kilian M. CRISPR/cas loci of type II Propionibacterium acnes confer immunity against acquisition of mobile elements present in type I P. acnes. PLoS ONE. 2012;7:e34171. doi: 10.1371/journal.pone.0034171.
    1. Sanford J.A., O’Neill A.M., Zouboulis C.C., Gallo R.L. Short-chain fatty acids from Cutibacterium acnes activate both a canonical and epigenetic inflammatory response in human sebocytes. J. Immunol. 2019;202:1767–1776. doi: 10.4049/jimmunol.1800893.
    1. Brüggemann H. Health Consequences of Microbial Interactions with Hydrocarbons, Oils, and Lipids. Handbook of Hydrocarbon and Lipid Microbiology. Springer; Cham, Switzerland: 2020. Skin: Cutibacterium (formerly Propionibacterium) acnes and Acne Vulgaris; pp. 225–243.
    1. O’Neill A.M., Gallo R.L. Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris. Microbiome. 2018;6:177. doi: 10.1186/s40168-018-0558-5.
    1. Andersson T., Bergdahl G.E., Saleh K., Magnúsdóttir H., Stødkilde K., Andersen C.B.F., Lundqvist K., Jensen A., Brüggemann H., Lood R. Common skin bacteria protect their host from oxidative stress through secreted antioxidant RoxP. Sci. Rep. 2019;9:1–10. doi: 10.1038/s41598-019-40471-3.
    1. Dréno B., Pécastaings S., Corvec S., Veraldi S., Khammari A., Roques C. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: A brief look at the latest updates. J. Eur. Acad. Dermatol. Venereol. 2018;32:5–14. doi: 10.1111/jdv.15043.
    1. Callewaert C., Knödlseder N., Karoglan A., Güell M., Paetzold B. Skin microbiome transplantation and manipulation: Current state of the art. Comput. Struct. Biotechnol. J. 2021;19:624–631. doi: 10.1016/j.csbj.2021.01.001.
    1. Deng Y., Wang H., Zhou J., Mou Y., Wang G., Xiong X. Patients with acne vulgaris have a distinct gut microbiota in comparison with healthy controls. Acta Derm. Venereol. 2018;98:783–790. doi: 10.2340/00015555-2968.
    1. Fabbrocini G., Bertona M., Picazo O., Pareja-Galeano H., Monfrecola G., Emanuele E. Supplementation with Lactobacillus rhamnosus SP1 normalises skin expression of genes implicated in insulin signalling and improves adult acne. Benef. Microbes. 2016;7:625–630. doi: 10.3920/BM2016.0089.
    1. Kim J., Ko Y., Park Y.K., Kim N.I., Ha W.K., Cho Y. Dietary effect of lactoferrin-enriched fermented milk on skin surface lipid and clinical improvement of acne vulgaris. Nutrition. 2010;26:902–909. doi: 10.1016/j.nut.2010.05.011.
    1. Melnik B.C. Linking diet to acne metabolomics, inflammation, and comedogenesis: An update. Clin. Cosmetic Investig. dermatol. 2015;8:371–388. doi: 10.2147/CCID.S69135.
    1. Bieber T. Mechanisms of disease. N. Engl. J. Med. 2008;358:1483–1494. doi: 10.1056/NEJMra074081.
    1. Williams H.C. Epidemiology of atopic dermatitis. Clin. Exp. Dermatol. 2000;25:522–529. doi: 10.1046/j.1365-2230.2000.00698.x.
    1. Brunner P.M., Guttman-Yassky E., Leung D.Y. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J. Allergy Clin. Immunol. 2017;139:S65–S76. doi: 10.1016/j.jaci.2017.01.011.
    1. Leung D.Y., Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches. J. Allergy Clin. Immunol. 2014;134:769–779. doi: 10.1016/j.jaci.2014.08.008.
    1. Cho S.H., Strickland I., Tomkinson A., Fehringer A.P., Gelfand E.W., Leung D.Y. Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model. J. Investig. Dermatol. 2001;116:658–663. doi: 10.1046/j.0022-202x.2001.01331.x.
    1. Morar N., Cookson W.O., Harper J.I., Moffatt M.F. Filaggrin mutations in children with severe atopic dermatitis. J. Investig. Dermatol. 2007;127:1667–1672. doi: 10.1038/sj.jid.5700739.
    1. Tanei R. Drugs & Aging. Springer; Cham, Switzerland: 2020. Atopic Dermatitis in Older Adults: A Review of Treatment Options; pp. 1–12.
    1. Paller A.S., Kabashima K., Bieber T. Therapeutic pipeline for atopic dermatitis: End of the drought? J. Allergy Clin. Immunol. 2017;140:633–643. doi: 10.1016/j.jaci.2017.07.006.
    1. Guttman-Yassky E., Pavel A.B., Zhou L., Estrada Y.D., Zhang N., Xu H., Peng X., Wen H.C., Govas P., Gudi G., et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2019;144:482–493. doi: 10.1016/j.jaci.2018.11.053.
    1. Shirley M. Dupilumab: First global approval. Drugs. 2017;77:1115–1121. doi: 10.1007/s40265-017-0768-3.
    1. Bjerre R., Bandier J., Skov L., Engstrand L., Johansen J. The role of the skin microbiome in atopic dermatitis: A systematic review. Br. J. Dermatol. 2017;177:1272–1278. doi: 10.1111/bjd.15390.
    1. Leyden J.J., Marples R.R., Kligman A.M. Staphylococcus aureus in the lesions of atopic dermatitis. Br. J. Dermatol. 1974;90:525. doi: 10.1111/j.1365-2133.1974.tb06447.x.
    1. Callewaert C., Nakatsuji T., Knight R., Kosciolek T., Vrbanac A., Kotol P., Ardeleanu M., Hultsch T., Guttman-Yassky E., Bissonnette R., et al. IL-4Rα blockade by dupilumab decreases Staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis. J. Investig. Dermatol. 2020;140:191–202. doi: 10.1016/j.jid.2019.05.024.
    1. Matsui K., Nishikawa A. Peptidoglycan-induced T helper 2 immune response in mice involves interleukin-10 secretion from Langerhans cells. Microbiol. Immunol. 2013;57:130–138. doi: 10.1111/j.1348-0421.2012.12006.x.
    1. Ruíz-González V., Cancino-Diaz J.C., Rodríguez-Martínez S., Cancino-Diaz M.E. Keratinocytes treated with peptidoglycan from Staphylococcus aureus produce vascular endothelial growth factor, and its expression is amplified by the subsequent production of interleukin-13. Int. J. Dermatol. 2009;48:846–854. doi: 10.1111/j.1365-4632.2008.03924.x.
    1. Travers J.B. Toxic interaction between Th2 cytokines and Staphylococcus aureus in atopic dermatitis. J. Investig. Dermatol. 2014;134:2069–2071. doi: 10.1038/jid.2014.122.
    1. Wollenberg A., Zoch C., Wetzel S., Plewig G., Przybilla B. Predisposing factors and clinical features of eczema herpeticum: A retrospective analysis of 100 cases. J. Am. Acad. Dermatol. 2003;49:198–205. doi: 10.1067/S0190-9622(03)00896-X.
    1. Mathes E.F., Oza V., Frieden I.J., Cordoro K.M., Yagi S., Howard R., Kristal L., Ginocchio C.C., Schaffer J., Maguiness S., et al. “Eczema coxsackium” and unusual cutaneous findings in an enterovirus outbreak. Pediatrics. 2013;132:e149–e157. doi: 10.1542/peds.2012-3175.
    1. Eichenfield L.F., Tom W.L., Berger T.G., Krol A., Paller A.S., Schwarzenberger K., Bergman J.N., Chamlin S.L., Cohen D.E., Cooper K.D., et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J. Am. Acad. Dermatol. 2014;71:116–132. doi: 10.1016/j.jaad.2014.03.023.
    1. Nakatsuji T., Chen T.H., Narala S., Chun K.A., Two A.M., Yun T., Shafiq F., Kotol P.F., Bouslimani A., Melnik A.V., et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci. Transl. Med. 2017;9:eaah4680. doi: 10.1126/scitranslmed.aah4680.
    1. Nylund L., Nermes M., Isolauri E., Salminen S., De Vos W., Satokari R. Severity of atopic disease inversely correlates with intestinal microbiota diversity and butyrate-producing bacteria. Allergy. 2015;70:241–244. doi: 10.1111/all.12549.
    1. Rather I.A., Bajpai V.K., Kumar S., Lim J., Paek W.K., Park Y.H. Probiotics and atopic dermatitis: An overview. Front. Microbiol. 2016;7:507. doi: 10.3389/fmicb.2016.00507.
    1. West C.E., Dzidic M., Prescott S.L., Jenmalm M.C. Bugging allergy; role of pre-, pro-and synbiotics in allergy prevention. Allergol. Int. 2017;66:529–538. doi: 10.1016/j.alit.2017.08.001.
    1. Piqué N., Berlanga M., Miñana-Galbis D. Health benefits of heat-killed (Tyndallized) probiotics: An overview. Int. J. Mol. Sci. 2019;20:2534. doi: 10.3390/ijms20102534.
    1. Chang Y.S., Trivedi M.K., Jha A., Lin Y.F., Dimaano L., Garcia-Romero M.T. Synbiotics for prevention and treatment of atopic dermatitis: A meta-analysis of randomized clinical trials. JAMA Pediatr. 2016;170:236–242. doi: 10.1001/jamapediatrics.2015.3943.
    1. Zuccotti G., Meneghin F., Aceti A., Barone G., Callegari M.L., Di Mauro A., Fantini M., Gori D., Indrio F., Maggio L., et al. Probiotics for prevention of atopic diseases in infants: Systematic review and meta-analysis. Allergy. 2015;70:1356–1371. doi: 10.1111/all.12700.
    1. Iemoli E., Trabattoni D., Parisotto S., Borgonovo L., Toscano M., Rizzardini G., Clerici M., Ricci E., Fusi A., De Vecchi E., et al. Probiotics reduce gut microbial translocation and improve adult atopic dermatitis. J. Clin. Gastroenterol. 2012;46:S33–S40. doi: 10.1097/MCG.0b013e31826a8468.
    1. Kim N.Y., Ji G.E. Effects of probiotics on the prevention of atopic dermatitis. Korean J. Pediatr. 2012;55:193. doi: 10.3345/kjp.2012.55.6.193.
    1. Kim J.E., Kim H.S. Microbiome of the skin and gut in atopic dermatitis (AD): Understanding the pathophysiology and finding novel management strategies. J. Clin. Med. 2019;8:444. doi: 10.3390/jcm8040444.
    1. Black P., Sharpe S. Dietary fat and asthma: Is there a connection? Eur. Respir. J. 1997;10:6–12. doi: 10.1183/09031936.97.10010006.
    1. Devereux G., Seaton A. Diet as a risk factor for atopy and asthma. J. Allergy Clin. Immunol. 2005;115:1109–1117. doi: 10.1016/j.jaci.2004.12.1139.
    1. Mabin D., Sykes A., David T. Controlled trial of a few foods diet in severe atopic dermatitis. Arch. Dis. Child. 1995;73:202–207. doi: 10.1136/adc.73.3.202.
    1. Caputo V., Strafella C., Termine A., Dattola A., Mazzilli S., Lanna C., Cosio T., Campione E., Novelli G., Giardina E., et al. Overview of the molecular determinants contributing to the expression of Psoriasis and Psoriatic Arthritis phenotypes. J. Cell. Mol. Med. 2020;24:13554–13563. doi: 10.1111/jcmm.15742.
    1. Nestle F., Kaplan D., Barker J. Mechanisms of Disease: Psoriasis. N. Engl. J. Med. 2009;361:496–509. doi: 10.1056/NEJMra0804595.
    1. Grine L., Lambert J. Psoriasis: Burning Down the Host. [(accessed on 15 November 2020)];2016 Available online: .
    1. Li Q., Chandran V., Tsoi L., O’Rielly D., Nair R.P., Gladman D., Elder J.T., Rahman P. Quantifying differences in heritability among psoriatic arthritis (PsA), cutaneous psoriasis (PsC) and psoriasis vulgaris (PsV) Sci. Rep. 2020;10:1–6. doi: 10.1038/s41598-020-61981-5.
    1. Dand N., Mahil S.K., Capon F., Smith C.H., Simpson M.A., Barker J.N. Psoriasis and genetics. Acta Derm Venereol. 2020;100:adv00030. doi: 10.2340/00015555-3384.
    1. Ovejero-Benito M.C., Muñoz-Aceituno E., Sabador D., Almoguera B., Prieto-Pérez R., Hakonarson H., Coto-Segura P., Carretero G., Reolid A., Llamas-Velasco M., et al. Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs. Exp. Dermatol. 2020;29:1225–1232. doi: 10.1111/exd.14215.
    1. Grozdev I., Korman N., Tsankov N. Psoriasis as a systemic disease. Clin. Dermatol. 2014;32:343–350. doi: 10.1016/j.clindermatol.2013.11.001.
    1. Takeshita J., Grewal S., Langan S.M., Mehta N.N., Ogdie A., Van Voorhees A.S., Gelfand J.M. Psoriasis and comorbid diseases: Implications for management. J. Am. Acad. Dermatol. 2017;76:393–403. doi: 10.1016/j.jaad.2016.07.065.
    1. Remröd C., Sjöström K., Svensson Å. Subjective stress reactivity in psoriasis–a cross sectional study of associated psychological traits. BMC Dermatol. 2015;15:6. doi: 10.1186/s12895-015-0026-x.
    1. Peters E.M. Stressed skin?–a molecular psychosomatic update on stress-causes and effects in dermatologic diseases. J. Der Dtsch. Dermatol. Ges. 2016;14:233–252. doi: 10.1111/ddg.12957.
    1. Grine L., Dejager L., Libert C., Vandenbroucke R.E. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17. Cytokine Growth Factor Rev. 2015;26:25–33. doi: 10.1016/j.cytogfr.2014.10.009.
    1. Li Y., Song Y., Zhu L., Wang X., Yang B., Lu P., Chen Q., Bin L., Deng L. Interferon Kappa Is Up-Regulated in Psoriasis and It Up-Regulates Psoriasis-Associated Cytokines in vivo. Clin. Cosmet. Investig. Dermatol. 2019;12:865. doi: 10.2147/CCID.S218243.
    1. Zhang L.j. Type1 interferons: Potential initiating factors linking skin wounds with psoriasis pathogenesis. Front. Immunol. 2019;10:1440. doi: 10.3389/fimmu.2019.01440.
    1. Conrad C., Di Domizio J., Mylonas A., Belkhodja C., Demaria O., Navarini A.A., Lapointe A.K., French L.E., Vernez M., Gilliet M. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat. Commun. 2018;9:1–11. doi: 10.1038/s41467-017-02466-4.
    1. Frasca L., Palazzo R., Chimenti M.S., Alivernini S., Tolusso B., Bui L., Botti E., Giunta A., Bianchi L., Petricca L., et al. Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: New biomarkers in PsA. Front. Immunol. 2018;9:1936. doi: 10.3389/fimmu.2018.01936.
    1. Kong H.H., Andersson B., Clavel T., Common J.E., Jackson S.A., Olson N.D., Segre J.A., Traidl-Hoffmann C. Performing skin microbiome research: A method to the madness. J. Investig. Dermatol. 2017;137:561–568. doi: 10.1016/j.jid.2016.10.033.
    1. Thorleifsdottir R.H., Sigurdardottir S.L., Sigurgeirsson B., Olafsson J.H., Sigurdsson M.I., Petersen H., Gudjonsson J.E., Johnston A., Valdimarsson H. Patient-reported outcomes and clinical response in patients with moderate-to-severe plaque psoriasis treated with tonsillectomy: A randomized controlled trial. Acta Derm. Venereol. 2017;97:340–345. doi: 10.2340/00015555-2562.
    1. Cohn J.E., Pfeiffer M., Vernose G. Complete resolution of guttate psoriasis after tonsillectomy. Ear, Nose Throat J. 2018;97:62–63. doi: 10.1177/014556131809700306.
    1. Haapasalo K., Koskinen L.L., Suvilehto J., Jousilahti P., Wolin A., Suomela S., Trembath R., Barker J., Vuopio J., Kere J., et al. The psoriasis risk allele HLA-C* 06: 02 shows evidence of association with chronic or recurrent streptococcal tonsillitis. Infect. Immun. 2018;86 doi: 10.1128/IAI.00304-18.
    1. Assarsson M., Duvetorp A., Dienus O., Söderman J., Seifert O. Significant changes in the skin microbiome in patients with chronic plaque psoriasis after treatment with narrowband ultraviolet B. Acta Derm. Venereol. 2018;98:428–436. doi: 10.2340/00015555-2859.
    1. Langan E., Künstner A., Miodovnik M., Zillikens D., Thaçi D., Baines J.F., Ibrahim S., Solbach W., Knobloch J. Combined culture and metagenomic analyses reveal significant shifts in the composition of the cutaneous microbiome in psoriasis. Br. J. Dermatol. 2019;181:1254–1264. doi: 10.1111/bjd.17989.
    1. Paniz Mondolfi A., Hernandez Perez M., Blohm G., Marquez M., Mogollon Mendoza A., Hernandez-Pereira C., Escalona M., Lodeiro Colatosti A., Rothe DeArocha J., Rodriguez Morales A. Generalized pustular psoriasis triggered by Zika virus infection. Clin. Exp. Dermatol. 2018;43:171–174. doi: 10.1111/ced.13294.
    1. Sbidian E., Madrange M., Viguier M., Salmona M., Duchatelet S., Hovnanian A., Smahi A., Le Goff J., Bachelez H. Respiratory virus infection triggers acute psoriasis flares across different clinical subtypes and genetic backgrounds. Br. J. Dermatol. 2019;181:1304–1306. doi: 10.1111/bjd.18203.
    1. Sanchez I.M., Jiang W., Yang E.J., Singh R.K., Beck K., Liu C., Afifi L., Liao W. Enteropathy in psoriasis: A systematic review of gastrointestinal disease epidemiology and subclinical inflammatory and functional gut alterations. Curr. Dermatol. Rep. 2018;7:59–74. doi: 10.1007/s13671-018-0213-1.
    1. Hueber W., Sands B.E., Lewitzky S., Vandemeulebroecke M., Reinisch W., Higgins P.D., Wehkamp J., Feagan B.G., Yao M.D., Karczewski M., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: Unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693–1700. doi: 10.1136/gutjnl-2011-301668.
    1. Fobelo Lozano M.J., Serrano Giménez R., Castro Fernández M. Emergence of inflammatory bowel disease during treatment with secukinumab. J. Crohn’s Colitis. 2018;12:1131–1133. doi: 10.1093/ecco-jcc/jjy063.
    1. Barry R., Salmon P., Read A., Warin R. Mucosal architecture of the small bowel in cases of psoriasis. Gut. 1971;12:873–877. doi: 10.1136/gut.12.11.873.
    1. Humbert P., Bidet A., Treffel P., Drobacheff C., Agache P. Intestinal permeability in patients with psoriasis. J. Dermatol. Sci. 1991;2:324–326. doi: 10.1016/0923-1811(91)90057-5.
    1. Sikora M., Stec A., Chrabaszcz M., Waskiel-Burnat A., Zaremba M., Olszewska M., Rudnicka L. Intestinal fatty acid binding protein, a biomarker of intestinal barrier, is associated with severity of psoriasis. J. Clin. Med. 2019;8:1021. doi: 10.3390/jcm8071021.
    1. Adarsh M., Dogra S., Vaiphei K., Vaishnavi C., Sinha S., Sharma A. Evaluation of subclinical gut inflammation using faecal calprotectin levels and colonic mucosal biopsy in patients with psoriasis and psoriatic arthritis. Br. J. Dermatol. 2019;181:401–402. doi: 10.1111/bjd.17745.
    1. Munz O.H., Sela S., Baker B.S., Griffiths C.E., Powles A.V., Fry L. Evidence for the presence of bacteria in the blood of psoriasis patients. Arch. Dermatol. Res. 2010;302:495–498. doi: 10.1007/s00403-010-1065-0.
    1. Ramírez-Boscá A., Navarro-López V., Martínez-Andrés A., Such J., Francés R., de la Parte J.H., Asín-Llorca M. Identification of bacterial DNA in the peripheral blood of patients with active psoriasis. JAMA Dermatol. 2015;151:670–671. doi: 10.1001/jamadermatol.2014.5585.
    1. Kim M., Han K.D., Lee J.H. Bodyweight variability and the risk of psoriasis: A nationwide population-based cohort study. J. Eur. Acad. Dermatol. Venereol. 2020;34:1019–1025. doi: 10.1111/jdv.16099.
    1. Jensen P., Christensen R., Zachariae C., Geiker N.R., Schaadt B.K., Stender S., Hansen P.R., Astrup A., Skov L. Long-term effects of weight reduction on the severity of psoriasis in a cohort derived from a randomized trial: A prospective observational follow-up study. Am. J. Clin. Nutr. 2016;104:259–265. doi: 10.3945/ajcn.115.125849.
    1. Nakamizo S., Honda T., Adachi A., Nagatake T., Kunisawa J., Kitoh A., Otsuka A., Dainichi T., Nomura T., Ginhoux F., et al. High fat diet exacerbates murine psoriatic dermatitis by increasing the number of IL-17-producing γδ T cells. Sci. Rep. 2017;7:1–13.
    1. Herbert D., Franz S., Popkova Y., Anderegg U., Schiller J., Schwede K., Lorz A., Simon J.C., Saalbach A. High-fat diet exacerbates early psoriatic skin inflammation independent of obesity: Saturated fatty acids as key players. J. Investig. Dermatol. 2018;138:1999–2009. doi: 10.1016/j.jid.2018.03.1522.
    1. Castaldo G., Galdo G., Aufiero F.R., Cereda E. Very low-calorie ketogenic diet may allow restoring response to systemic therapy in relapsing plaque psoriasis. Obes. Res. Clin. Pract. 2016;10:348–352. doi: 10.1016/j.orcp.2015.10.008.
    1. Damiani G., Watad A., Bridgewood C., Pigatto P.D.M., Pacifico A., Malagoli P., Bragazzi N.L., Adawi M. The impact of ramadan fasting on the reduction of PASI score, in moderate-to-severe psoriatic patients: A real-life multicenter study. Nutrients. 2019;11:277. doi: 10.3390/nu11020277.
    1. Codoñer F.M., Ramírez-Bosca A., Climent E., Carrión-Gutierrez M., Guerrero M., Pérez-Orquín J.M., De La Parte J.H., Genovés S., Ramón D., Navarro-López V., et al. Gut microbial composition in patients with psoriasis. Sci. Rep. 2018;8:1–7. doi: 10.1038/s41598-018-22125-y.
    1. Navarro-López V., Martínez-Andrés A., Ramírez-Boscá A., Ruzafa-Costas B., Núñez-Delegido E., Carrión-Gutiérrez M.A., Prieto-Merino D., Codoñer-Cortés F., Ramón-Vidal D., Genovés-Martínez S., et al. Efficacy and safety of oral administration of a mixture of probiotic strains in patients with psoriasis: A randomized controlled clinical trial. Acta Derm. Venereol. 2019;99:1078–1084. doi: 10.2340/00015555-3305.
    1. Itano A., Cormack T., Ramani K., Barth K., Wang I., Mukherjee A., Ponichtera H., McKenna C., Jahic M., Bodmer M. Orally-administered EDP1815, a single strain of Prevotella histicola, has potent systemic anti-inflammatory effects in Type 1, Type 2, and Type 3 inflammatory models; Proceedings of the 29th European Academy of Dermatology and Venereology Congress (EADV); Vienna, Austria. 29–31 October 2020.
    1. Phan K., Charlton O., Smith S.D. Global prevalence of hidradenitis suppurativa and geographical variation—systematic review and meta-analysis. Biomed. Dermatol. 2020;4:1–6. doi: 10.1186/s41702-019-0052-0.
    1. Jørgensen A.H.R., Thomsen S.F., Karmisholt K.E., Ring H.C. Clinical, microbiological, immunological and imaging characteristics of tunnels and fistulas in hidradenitis suppurativa and Crohn’s disease. Exp. Dermatol. 2020;29:118–123. doi: 10.1111/exd.14036.
    1. Moran B., Sweeney C.M., Hughes R., Malara A., Kirthi S., Tobin A.M., Kirby B., Fletcher J.M. Hidradenitis suppurativa is characterized by dysregulation of the Th17: Treg cell axis, which is corrected by anti-TNF therapy. J. Investig. Dermatol. 2017;137:2389–2395. doi: 10.1016/j.jid.2017.05.033.
    1. Chen W.T., Chi C.C. Association of hidradenitis suppurativa with inflammatory bowel disease: A systematic review and meta-analysis. JAMA Dermatol. 2019;155:1022–1027. doi: 10.1001/jamadermatol.2019.0891.
    1. Giudici F., Maggi L., Santi R., Cosmi L., Scaletti C., Annunziato F., Nesi G., Barra G., Bassotti G., De Palma R., et al. Perianal Crohn’s disease and hidradenitis suppurativa: A possible common immunological scenario. Clin. Mol. Allergy. 2015;13:12. doi: 10.1186/s12948-015-0018-8.
    1. Barta Z., Zöld É., Csípõ I., Zeher M. ASCAs in (auto-) Immune Small Bowel Diseases. [(accessed on 20 November 2020)];2020 Available online: .
    1. Denny G., Anadkat M.J. The effect of smoking and age on the response to first-line therapy of hidradenitis suppurativa: An institutional retrospective cohort study. J. Am. Acad. Dermatol. 2017;76:54–59. doi: 10.1016/j.jaad.2016.07.041.
    1. König A., Lehmann C., Rompel R., Happle R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology. 1999;198:261–264. doi: 10.1159/000018126.
    1. Kromann C.B., Ibler K.S., Kristiansen V.B., Jemec G.B. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm. Venereol. 2014;94:553–557. doi: 10.2340/00015555-1800.
    1. Aboud C., Zamaria N., Cannistrà C. Treatment of hidradenitis suppurativa: Surgery and yeast (Saccharomyces cerevisiae)–exclusion diet. Results after 6 years. Surgery. 2020;167:1012–1015. doi: 10.1016/j.surg.2019.12.015.
    1. Silfvast-Kaiser A., Youssef R., Paek S.Y. Diet in hidradenitis suppurativa: A review of published and lay literature. Int. J. Dermatol. 2019;58:1225–1230. doi: 10.1111/ijd.14465.
    1. Buechner S.A. Rosacea: An update. Dermatology. 2005;210:100–108. doi: 10.1159/000082564.
    1. Rainer B.M., Fischer A.H., Da Silva D.L.F., Kang S., Chien A.L. Rosacea is associated with chronic systemic diseases in a skin severity–dependent manner: Results of a case-control study. J. Am. Acad. Dermatol. 2015;73:604–608. doi: 10.1016/j.jaad.2015.07.009.
    1. Tan J., Berg M. Rosacea: Current state of epidemiology. J. Am. Acad. Dermatol. 2013;69:S27–S35. doi: 10.1016/j.jaad.2013.04.043.
    1. Duman N., Ersoy Evans S., Atakan N. Rosacea and cardiovascular risk factors: A case control study. J. Eur. Acad. Dermatol. Venereol. 2014;28:1165–1169. doi: 10.1111/jdv.12234.
    1. Yamasaki K., Di Nardo A., Bardan A., Murakami M., Ohtake T., Coda A., Dorschner R.A., Bonnart C., Descargues P., Hovnanian A., et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat. Med. 2007;13:975–980. doi: 10.1038/nm1616.
    1. Nizet V., Ohtake T., Lauth X., Trowbridge J., Rudisill J., Dorschner R.A., Pestonjamasp V., Piraino J., Huttner K., Gallo R.L. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature. 2001;414:454–457. doi: 10.1038/35106587.
    1. Two A.M., Wu W., Gallo R.L., Hata T.R. Rosacea: Part I. Introduction, categorization, histology, pathogenesis, and risk factors. J. Am. Acad. Dermatol. 2015;72:749–758. doi: 10.1016/j.jaad.2014.08.028.
    1. Gallo R.L., Ono M., Povsic T., Page C., Eriksson E., Klagsbrun M., Bernfield M. Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc. Natl. Acad. Sci. USA. 1994;91:11035–11039. doi: 10.1073/pnas.91.23.11035.
    1. Yang D., Chen Q., Schmidt A.P., Anderson G.M., Wang J.M., Wooters J., Oppenheim J.J., Chertov O. LL-37, the neutrophil granule–and epithelial cell–derived cathelicidin, utilizes formyl peptide receptor–like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 2000;192:1069–1074. doi: 10.1084/jem.192.7.1069.
    1. Koczulla R., Von Degenfeld G., Kupatt C., Krötz F., Zahler S., Gloe T., Issbrücker K., Unterberger P., Zaiou M., Lebherz C., et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Investig. 2003;111:1665–1672. doi: 10.1172/JCI17545.
    1. Sulk M., Seeliger S., Aubert J., Schwab V.D., Cevikbas F., Rivier M., Nowak P., Voegel J.J., Buddenkotte J., Steinhoff M. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea. J. Investig. Dermatol. 2012;132:1253–1262. doi: 10.1038/jid.2011.424.
    1. Ferrer L., Ravera I., Silbermayr K. Immunology and pathogenesis of canine demodicosis. Vet. Dermatol. 2014;25:427–e65. doi: 10.1111/vde.12136.
    1. Kocak M., Yagli S., Vahapoğlu G., Ekşioğlu M. Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology. 2002;205:265–270. doi: 10.1159/000065849.
    1. O’Reilly N., Menezes N., Kavanagh K. Positive correlation between serum immunoreactivity to Demodex-associated Bacillus proteins and erythematotelangiectatic rosacea. Br. J. Dermatol. 2012;167:1032–1036. doi: 10.1111/j.1365-2133.2012.11114.x.
    1. Yamasaki K., Gallo R.L. The molecular pathology of rosacea. J. Dermatol. Sci. 2009;55:77–81. doi: 10.1016/j.jdermsci.2009.04.007.
    1. Woo Y.R., Lee S.H., Cho S.H., Lee J.D., Kim H.S. Characterization and Analysis of the Skin Microbiota in Rosacea: Impact of Systemic Antibiotics. J. Clin. Med. 2020;9:185. doi: 10.3390/jcm9010185.
    1. Eriksson G., Nord C. Impact of topical metronidazole on the skin and colon microflora in patients with rosacea. Infection. 1987;15:8–10. doi: 10.1007/BF01646108.
    1. Zaidi A.K., Spaunhurst K., Sprockett D., Thomason Y., Mann M.W., Fu P., Ammons C., Gerstenblith M., Tuttle M.S., Popkin D.L. Characterization of the facial microbiome in twins discordant for rosacea. Exp. Dermatol. 2018;27:295–298. doi: 10.1111/exd.13491.
    1. Weiss E., Katta R. Diet and rosacea: The role of dietary change in the management of rosacea. Dermatol. Pract. Concept. 2017;7:31. doi: 10.5826/dpc.0704a08.
    1. Egeberg A., Weinstock L., Thyssen E., Gislason G., Thyssen J. Rosacea and gastrointestinal disorders: A population-based cohort study. Br. J. Dermatol. 2017;176:100–106. doi: 10.1111/bjd.14930.
    1. Chen Y.J., Lee W.H., Ho H.J., Tseng C.H., Wu C.Y. An altered fecal microbial profiling in rosacea patients compared to matched controls. J. Formos. Med. Assoc. 2020;120:256–264. doi: 10.1016/j.jfma.2020.04.034.
    1. Gupta V.K., Paul S., Dutta C. Geography, ethnicity or subsistence-specific variations in human microbiome composition and diversity. Front. Microbiol. 2017;8:1162. doi: 10.3389/fmicb.2017.01162.
    1. Scheman A., Rakowski E.M., Chou V., Chhatriwala A., Ross J., Jacob S.E. Balsam of Peru: Past and future. Dermatitis. 2013;24:153–160. doi: 10.1097/DER.0b013e31828afab2.
    1. Aubdool A.A., Brain S.D. Neurovascular aspects of skin neurogenic inflammation. J. Investig. Dermatol. Symp. Proc. 2011;15:33–39. doi: 10.1038/jidsymp.2011.8.
    1. Kamamoto C., Nishikaku A., Gompertz O., Melo A., Hassun K., Bagatin E. Cutaneous fungal microbiome: Malassezia yeasts in seborrheic dermatitis scalp in a randomized, comparative and therapeutic trial. Dermato-endocrinology. 2017;9:e1361573. doi: 10.1080/19381980.2017.1361573.
    1. Tucker D., Masood S. StatPearls [Internet] StatPearls Publishing; Treasure Island, FL, USA: 2019. Seborrheic Dermatitis.
    1. Borda L.J., Wikramanayake T.C. Seborrheic dermatitis and dandruff: A comprehensive review. J. Clin. Investig. Dermatol. 2015;3 doi: 10.13188/2373-1044.1000019.
    1. Mokos Z.B., Kralj M., Basta-Juzbasic A., Jukic I.L. Seborrheic dermatitis: An update. Acta Dermatovenerol Croat. 2012;20:98–104.
    1. Rudramurthy S.M., Honnavar P., Chakrabarti A., Dogra S., Singh P., Handa S. Association of Malassezia species with psoriatic lesions. Mycoses. 2014;57:483–488. doi: 10.1111/myc.12186.
    1. DeAngelis Y.M., Gemmer C.M., Kaczvinsky J.R., Kenneally D.C., Schwartz J.R., Dawson T.L., Jr. Three etiologic facets of dandruff and seborrheic dermatitis: Malassezia fungi, sebaceous lipids, and individual sensitivity. J. Investig. Dermatol. Symp. Proc. 2005;10:295–297. doi: 10.1111/j.1087-0024.2005.10119.x.
    1. Odintsova I., Dyudyun A. Features of the composition of microorganisms inhabiting the intestinal mucosa in patients with seborrheic dermatitis. Dermatovenerol. Cosmetol. Sexopathol. 2019:31–34. doi: 10.37321/dermatology.2019.1-2-05.
    1. Sakuma T.H., Maibach H.I. Oily skin: An overview. Skin Pharmacol. Physiol. 2012;25:227–235. doi: 10.1159/000338978.
    1. Bett D., Morland J., Yudkin J. Sugar consumption in acne vulgaris and seborrhoeic dermatitis. Br. Med J. 1967;3:153. doi: 10.1136/bmj.3.5558.153.
    1. Pochi P.E., Downing D.T., Strauss J.S. Sebaceous gland response in man to prolonged total caloric deprivation. J. Investig. Dermatol. 1970;55:303–309. doi: 10.1111/1523-1747.ep12260136.
    1. Boelsma E., Van de Vijver L.P., Goldbohm R.A., Klöpping-Ketelaars I.A., Hendriks H.F., Roza L. Human skin condition and its associations with nutrient concentrations in serum and diet. Am. J. Clin. Nutr. 2003;77:348–355. doi: 10.1093/ajcn/77.2.348.
    1. Tamer F. Relationship between diet and seborrheic dermatitis. Our Dermatol. Online. 2018;9:261–264. doi: 10.7241/ourd.20183.6.
    1. Lee H.H., Gwillim E., Patel K.R., Hua T., Rastogi S., Ibler E., Silverberg J.I. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis. J. Am. Acad. Dermatol. 2020;82:675–682. doi: 10.1016/j.jaad.2019.08.032.
    1. Simakou T., Butcher J.P., Reid S., Henriquez F.L. Alopecia areata: A multifactorial autoimmune condition. J. Autoimmun. 2019;98:74–85. doi: 10.1016/j.jaut.2018.12.001.
    1. Juhasz M., Chen S., Khosrovi-Eghbal A., Ekelem C., Landaverde Y., Baldi P., Mesinkovska N.A. Characterizing the Skin and Gut Microbiome of Alopecia Areata Patients. SKIN J. Cutan. Med. 2020;4:23–30. doi: 10.25251/skin.4.1.4.
    1. Polak-Witka K., Rudnicka L., Blume-Peytavi U., Vogt A. The role of the microbiome in scalp hair follicle biology and disease. Exp. Dermatol. 2020;29:286–294. doi: 10.1111/exd.13935.
    1. Migacz-Gruszka K., Branicki W., Obtulowicz A., Pirowska M., Gruszka K., Wojas-Pelc A. What’s new in the pathophysiology of alopecia areata? the possible contribution of skin and gut microbiome in the pathogenesis of alopecia–Big opportunities, big challenges, and novel perspectives. Int. J. Trichology. 2019;11:185. doi: 10.4103/ijt.ijt_76_19.
    1. Guo E.L., Katta R. Diet and hair loss: Effects of nutrient deficiency and supplement use. Dermatol. Pract. Concept. 2017;7:1. doi: 10.5826/dpc.0701a01.
    1. Pham C.T., Romero K., Almohanna H.M., Griggs J., Ahmed A., Tosti A. The Role of Diet as an Adjuvant Treatment in Scarring and Nonscarring Alopecia. Skin Appendage Disord. 2020;6:88–96. doi: 10.1159/000504786.
    1. Grosu-Bularda A., Lăzărescu L., Stoian A., Lascăr I. Immunology and skin cancer. Arch. Clin. Cases. 2018;5 doi: 10.22551/2018.20.0503.10137.
    1. Carr S., Smith C., Wernberg J. Epidemiology and risk factors of melanoma. Surg. Clin. 2020;100:1–12. doi: 10.1016/j.suc.2019.09.005.
    1. Marks R. An overview of skin cancers. Cancer. 1995;75:607–612. doi: 10.1002/1097-0142(19950115)75:2+<607::AID-CNCR2820751402>;2-8.
    1. Rangwala S., Tsai K. Roles of the immune system in skin cancer. Br. J. Dermatol. 2011;165:953–965. doi: 10.1111/j.1365-2133.2011.10507.x.
    1. Vergara D., Simeone P., Damato M., Maffia M., Lanuti P., Trerotola M. The cancer microbiota: EMT and inflammation as shared molecular mechanisms associated with plasticity and progression. J. Oncol. 2019;2019:1253727. doi: 10.1155/2019/1253727.
    1. Nakatsuji T., Chen T.H., Butcher A.M., Trzoss L.L., Nam S.J., Shirakawa K.T., Zhou W., Oh J., Otto M., Fenical W., et al. A commensal strain of Staphylococcus epidermidis protects against skin neoplasia. Sci. Adv. 2018;4:eaao4502. doi: 10.1126/sciadv.aao4502.
    1. Allhorn M., Arve S., Brüggemann H., Lood R. A novel enzyme with antioxidant capacity produced by the ubiquitous skin colonizer Propionibacterium acnes. Sci. Rep. 2016;6:36412. doi: 10.1038/srep36412.
    1. Frosali S., Pagliari D., Gambassi G., Landolfi R., Pandolfi F., Cianci R. How the intricate interaction among toll-like receptors, microbiota, and intestinal immunity can influence gastrointestinal pathology. J. Immunol. Res. 2015;2015:489821. doi: 10.1155/2015/489821.
    1. Eming S.A., Martin P., Tomic-Canic M. Wound repair and regeneration: Mechanisms, signaling, and translation. Sci. Transl. Med. 2014;6:265sr6. doi: 10.1126/scitranslmed.3009337.
    1. Heyer K., Herberger K., Protz K., Glaeske G., Augustin M. Epidemiology of chronic wounds in Germany: Analysis of statutory health insurance data. Wound Repair Regen. 2016;24:434–442. doi: 10.1111/wrr.12387.
    1. Guest J.F., Ayoub N., McIlwraith T., Uchegbu I., Gerrish A., Weidlich D., Vowden K., Vowden P. Health economic burden that wounds impose on the National Health Service in the UK. BMJ Open. 2015;5 doi: 10.1136/bmjopen-2015-009283.
    1. Gould L., Abadir P., Brem H., Carter M., Conner-Kerr T., Davidson J., DiPietro L., Falanga V., Fife C., Gardner S., et al. Chronic wound repair and healing in older adults: Current status and future research. Wound Repair Regen. 2015;23:1–13. doi: 10.1111/wrr.12245.
    1. Sawaya A.P., Stone R.C., Brooks S.R., Pastar I., Jozic I., Hasneen K., O’Neill K., Mehdizadeh S., Head C.R., Strbo N., et al. Deregulated immune cell recruitment orchestrated by FOXM1 impairs human diabetic wound healing. Nat. Commun. 2020;11:1–14. doi: 10.1038/s41467-020-18276-0.
    1. Tomic-Canic M., Burgess J.L., O’Neill K.E., Strbo N., Pastar I. Skin Microbiota and its Interplay with Wound Healing. Am. J. Clin. Dermatol. 2020;21:36–43. doi: 10.1007/s40257-020-00536-w.
    1. Ramirez H.A., Pastar I., Jozic I., Stojadinovic O., Stone R.C., Ojeh N., Gil J., Davis S.C., Kirsner R.S., Tomic-Canic M. Staphylococcus aureus triggers induction of miR-15B-5P to diminish DNA repair and deregulate inflammatory response in diabetic foot ulcers. J. Investig. Dermatol. 2018;138:1187–1196. doi: 10.1016/j.jid.2017.11.038.
    1. Stone R.C., Stojadinovic O., Rosa A.M., Ramirez H.A., Badiavas E., Blumenberg M., Tomic-Canic M. A bioengineered living cell construct activates an acute wound healing response in venous leg ulcers. Sci. Transl. Med. 2017;9:eaaf8611. doi: 10.1126/scitranslmed.aaf8611.
    1. Stone R.C., Stojadinovic O., Sawaya A.P., Glinos G.D., Lindley L.E., Pastar I., Badiavas E., Tomic-Canic M. A bioengineered living cell construct activates metallothionein/zinc/MMP8 and inhibits TGFβ to stimulate remodeling of fibrotic venous leg ulcers. Wound Repair Regen. 2020;28:164–176. doi: 10.1111/wrr.12778.
    1. Pastar I., Wong L.L., Egger A.N., Tomic-Canic M. Descriptive vs mechanistic scientific approach to study wound healing and its inhibition: Is there a value of translational research involving human subjects? Exp. Dermatol. 2018;27:551–562. doi: 10.1111/exd.13663.
    1. Thom S.R., Hampton M., Troiano M.A., Mirza Z., Malay D.S., Shannon S., Jennato N.B., Donohue C.M., Hoffstad O., Woltereck D., et al. Measurements of CD34+/CD45-dim stem cells predict healing of diabetic neuropathic wounds. Diabetes. 2016;65:486–497. doi: 10.2337/db15-0517.
    1. Zeeuwen P.L., Boekhorst J., van den Bogaard E.H., de Koning H.D., van de Kerkhof P.M., Saulnier D.M., van Swam I.I., van Hijum S.A., Kleerebezem M., Schalkwijk J., et al. Microbiome dynamics of human epidermis following skin barrier disruption. Genome Biol. 2012;13:1–18. doi: 10.1186/gb-2012-13-11-r101.
    1. Pastar I., Nusbaum A.G., Gil J., Patel S.B., Chen J., Valdes J., Stojadinovic O., Plano L.R., Tomic-Canic M., Davis S.C. Interactions of methicillin resistant Staphylococcus aureus USA300 and Pseudomonas aeruginosa in polymicrobial wound infection. PLoS ONE. 2013;8:e56846. doi: 10.1371/journal.pone.0056846.
    1. Harrison O.J., Linehan J.L., Shih H.Y., Bouladoux N., Han S.J., Smelkinson M., Sen S.K., Byrd A.L., Enamorado M., Yao C., et al. Commensal-specific T cell plasticity promotes rapid tissue adaptation to injury. Science. 2019;363:eaat6280. doi: 10.1126/science.aat6280.
    1. Lai Y., Di Nardo A., Nakatsuji T., Leichtle A., Yang Y., Cogen A.L., Wu Z.R., Hooper L.V., Schmidt R.R., Von Aulock S., et al. Commensal bacteria regulate Toll-like receptor 3–dependent inflammation after skin injury. Nat. Med. 2009;15:1377. doi: 10.1038/nm.2062.
    1. McCormack R.M., de Armas L.R., Shiratsuchi M., Fiorentino D.G., Olsson M.L., Lichtenheld M.G., Morales A., Lyapichev K., Gonzalez L.E., Strbo N., et al. Perforin-2 is essential for intracellular defense of parenchymal cells and phagocytes against pathogenic bacteria. Elife. 2015;4:e06508. doi: 10.7554/eLife.06508.
    1. Pastar I., O’Neill K., Padula L., Head C.R., Burgess J.L., Chen V., Garcia D., Stojadinovic O., Hower S., Plano G.V., et al. Staphylococcus epidermidis boosts innate immune response by activation of Gamma Delta T cells and induction of Perforin-2 in human skin. Front. Immunol. 2020;11:2253. doi: 10.3389/fimmu.2020.550946.
    1. Luqman A., Muttaqin M.Z., Yulaipi S., Ebner P., Matsuo M., Zabel S., Tribelli P.M., Nieselt K., Hidayati D., Götz F. Trace amines produced by skin bacteria accelerate wound healing in mice. Commun. Biol. 2020;3:1–10. doi: 10.1038/s42003-020-1000-7.
    1. Misic A.M., Gardner S.E., Grice E.A. The wound microbiome: Modern approaches to examining the role of microorganisms in impaired chronic wound healing. Adv. Wound Care. 2014;3:502–510. doi: 10.1089/wound.2012.0397.
    1. Kalan L.R., Meisel J.S., Loesche M.A., Horwinski J., Soaita I., Chen X., Uberoi A., Gardner S.E., Grice E.A. Strain-and species-level variation in the microbiome of diabetic wounds is associated with clinical outcomes and therapeutic efficacy. Cell Host Microbe. 2019;25:641–655. doi: 10.1016/j.chom.2019.03.006.
    1. Huseini H.F., Rahimzadeh G., Fazeli M.R., Mehrazma M., Salehi M. Evaluation of wound healing activities of kefir products. Burns. 2012;38:719–723. doi: 10.1016/j.burns.2011.12.005.
    1. Poutahidis T., Kearney S.M., Levkovich T., Qi P., Varian B.J., Lakritz J.R., Ibrahim Y.M., Chatzigiagkos A., Alm E.J., Erdman S.E. Microbial symbionts accelerate wound healing via the neuropeptide hormone oxytocin. PLoS ONE. 2013;8:e78898. doi: 10.1371/journal.pone.0078898.
    1. Levkovich T., Poutahidis T., Smillie C., Varian B.J., Ibrahim Y.M., Lakritz J.R., Alm E.J., Erdman S.E. Probiotic bacteria induce a ‘glow of health’. PLoS ONE. 2013;8:e53867. doi: 10.1371/journal.pone.0053867.
    1. Gueniche A., Philippe D., Bastien P., Reuteler G., Blum S., Castiel-Higounenc I., Breton L., Benyacoub J. Randomised double-blind placebo-controlled study of the effect of Lactobacillus paracasei NCC 2461 on skin reactivity. Benef. Microbes. 2014;5:137–145. doi: 10.3920/BM2013.0001.
    1. Krutmann J. Pre-and probiotics for human skin. J. Dermatol. Sci. 2009;54:1–5. doi: 10.1016/j.jdermsci.2009.01.002.
    1. Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., Morelli L., Canani R.B., Flint H.J., Salminen S., et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014;11:506. doi: 10.1038/nrgastro.2014.66.
    1. Farris P.K. Are skincare products with probiotics worth the hype? DermatologyTimes. [(accessed on 20 November 2020)];2016 Available online: .
    1. Grant M.C., Baker J.S. An overview of the effect of probiotics and exercise on mood and associated health conditions. Crit. Rev. Food Sci. Nutr. 2017;57:3887–3893. doi: 10.1080/10408398.2016.1189872.
    1. Sánchez B., Delgado S., Blanco-Míguez A., Lourenço A., Gueimonde M., Margolles A. Probiotics, gut microbiota, and their influence on host health and disease. Mol. Nutr. Food Res. 2017;61:1600240. doi: 10.1002/mnfr.201600240.
    1. Sarao L.K., Arora M. Probiotics, prebiotics, and microencapsulation: A review. Crit. Rev. Food Sci. Nutr. 2017;57:344–371. doi: 10.1080/10408398.2014.887055.
    1. Muizzuddin N., Maher W., Sullivan M., Schnittger S., Mammone T. Physiological effect of a probiotic on skin. J. Cosmet. Sci. 2012;63:385–395.
    1. Frei R., Akdis M., O’Mahony L. Prebiotics, probiotics, synbiotics, and the immune system: Experimental data and clinical evidence. Curr. Opin. Gastroenterol. 2015;31:153–158. doi: 10.1097/MOG.0000000000000151.
    1. Longo V.D., Cortellino S. Fasting, dietary restriction, and immunosenescence. J. Allergy Clin. Immunol. 2020;146:1002–1004. doi: 10.1016/j.jaci.2020.07.035.
    1. Bronsnick T., Murzaku E.C., Rao B.K. Diet in dermatology: Part I. Atopic dermatitis, acne, and nonmelanoma skin cancer. J. Am. Acad. Dermatol. 2014;71:1039–e1. doi: 10.1016/j.jaad.2014.06.015.
    1. Parkar S.G., Kalsbeek A., Cheeseman J.F. Potential role for the gut microbiota in modulating host circadian rhythms and metabolic health. Microorganisms. 2019;7:41. doi: 10.3390/microorganisms7020041.
    1. Voigt R., Forsyth C., Green S., Engen P., Keshavarzian A. International Review of Neurobiology. Volume 131. Elsevier; Amsterdam, The Netherlands: 2016. Circadian rhythm and the gut microbiome; pp. 193–205.
    1. Deaver J.A., Eum S.Y., Toborek M. Circadian disruption changes gut microbiome taxa and functional gene composition. Front. Microbiol. 2018;9:737. doi: 10.3389/fmicb.2018.00737.
    1. Zeb F., Wu X., Chen L., Fatima S., Haq I.u., Chen A., Majeed F., Feng Q., Li M. Effect of time-restricted feeding on metabolic risk and circadian rhythm associated with gut microbiome in healthy males. Br. J. Nutr. 2020;123:1216–1226. doi: 10.1017/S0007114519003428.
    1. Jakubowicz D., Barnea M., Wainstein J., Froy O. High caloric intake at breakfast vs. dinner differentially influences weight loss of overweight and obese women. Obesity. 2013;21:2504–2512. doi: 10.1002/oby.20460.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj